Kayla Ann AndrewsDavid WescheJames McCarthyJörg J. MöhrleJoel TarningLuann PhillipsSteven KernThaddeus GraselaUniversity at Buffalo, State University of New YorkUniversity of QueenslandQIMR Berghofer Medical Research InstituteBill and Melinda Gates FoundationMahidol UniversityNuffield Department of Clinical MedicineCognigen CorporationMedicines for Malaria Venture2019-08-282019-08-282018-01-06Annual Review of Pharmacology and Toxicology. Vol.58, (2018), 567-58215454304036216422-s2.0-85040632198https://repository.li.mahidol.ac.th/handle/20.500.14594/47328© 2018 Kayla Ann Andrews et al. Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate the development efforts of new malaria therapeutics are urgently needed. There have been significant advancements in the development of in vitro and in vivo experiments that generate data used to inform decisions about the potential merit of new compounds. A comprehensive disease-drug model capable of integrating discrete data from different preclinical and clinical components would be a valuable tool across all stages of drug development. This could have an enormous impact on the otherwise slow and resource-intensive process of traditional clinical drug development.Mahidol UniversityPharmacology, Toxicology and PharmaceuticsReviewSCOPUS10.1146/annurev-pharmtox-010715-103429